National comprehensive cancer network (NCCN) recommendations for drugs without US food and drug administration (FDA) approval in metastatic breast cancer: A cross-sectional study

被引：0
|
作者：
Etan, Tal [1 ]
Amir, Eitan [2 ]
Tibau, Adriana [3 ]
Yerushalmi, Rinat [4 ]
Moore, Assaf [4 ]
Shepshelovich, Daniel [1 ]
Goldvaser, Hadar [4 ]
机构：
[1] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[2] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
[4] Rabin Med Ctr, Petah Tiqwa, Israel
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS14-13
引用
收藏
页数：1
相关论文
共 50 条
  • [31] US Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer
    Ribeiro, Tatiane Bomfim
    Ribeiro, Adalton
    Rodrigues, Luiza de Oliveira
    Harada, Guilherme
    Nobre, Moacyr Roberto Cuce
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2020, 36 (01) : 20 - 28
  • [32] Complete remission in metastatic breast cancer: expecting the unexpected—results of a cross-sectional study
    Giulia Galli
    Anna Tessari
    Luca Porcu
    Giacomo Bregni
    Biagio Paolini
    Maria Luisa Carcangiu
    Massimiliano Gennaro
    Maria Carmen De Santis
    Laura Lozza
    Filippo de Braud
    Serena Di Cosimo
    Breast Cancer, 2017, 24 : 635 - 641
  • [33] ONCOLOGY MEDICATION UTILIZATION BASED ON FEDERAL DRUG ADMINISTRATION (FDA) LABELING, NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) CLINICAL PRACTICE GUIDELINE (GL) RECOMMENDATIONS, AND EVIDENCE FOR PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER (NSCLC): AN ANALYSIS FROM THE NCCN ONCOLOGY OUTCOMES DATABASE
    Lepisto, E. M.
    Vandergrift, J. L.
    Kalemkerian, G. P.
    Pisters, K. M.
    Zornosa, C.
    Rabin, M. S.
    Reid, M. E.
    Koczywas, M.
    Otterson, G. A.
    Ettinger, D. S.
    VALUE IN HEALTH, 2011, 14 (03) : A176 - A177
  • [34] Pelvic floor muscle function in women with and without breast cancer: A cross-sectional study
    Colombage, Udari N.
    Soh, Sze-Ee
    Lin, Kuan-Yin
    Frawley, Helena C.
    CONTINENCE, 2023, 5
  • [35] Financial toxicity in female patients with breast cancer: a national cross-sectional study in China
    Liu, Meicen
    Hu, Linlin
    Han, Xueyan
    Cao, Man
    Sun, Jing
    Liu, Yuanli
    SUPPORTIVE CARE IN CANCER, 2022, 30 (10) : 8231 - 8240
  • [36] Financial toxicity in female patients with breast cancer: a national cross-sectional study in China
    Meicen Liu
    Linlin Hu
    Xueyan Han
    Man Cao
    Jing Sun
    Yuanli Liu
    Supportive Care in Cancer, 2022, 30 : 8231 - 8240
  • [37] Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending
    Michaeli, Thomas
    Michaeli, Daniel Tobias
    VALUE IN HEALTH, 2024, 27 (04) : 449 - 457
  • [38] US Food and Drug Administration recalls of cosmetic and personal products from 2011 to 2023: A cross-sectional study
    Venkatesh, Kaushik P.
    Kadakia, Kushal T.
    Akbarpour, Ashkan
    Nambudiri, Vinod E.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2025, 92 (01) : 179 - 181
  • [39] Gastrointestinal (GI) cancer (CA) drugs approved by the US Food and Drug Administration (FDA): Clinical value and cost considerations.
    Jiang, Di Maria
    Jang, Raymond Woo-Jun
    Chan, Kelvin K.
    Liu, Geoffrey
    Amir, Eitan
    Elimova, Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [40] Complete remission in metastatic breast cancer: expecting the unexpected-results of a cross-sectional study
    Galli, Giulia
    Tessari, Anna
    Porcu, Luca
    Bregni, Giacomo
    Paolini, Biagio
    Carcangiu, Maria Luisa
    Gennaro, Massimiliano
    De Santis, Maria Carmen
    Lozza, Laura
    de Braud, Filippo
    Di Cosimo, Serena
    BREAST CANCER, 2017, 24 (04) : 635 - 641
12345